Cyclic polypeptide produced THERAPEUTIC

Health hazards

INFORMATION OSHA EMERGENCY CAUTION – The information in this MSDS is based on the hazards of the OVERVIEW active ingredient. While diluted, this material may present the following

SECTION 2: Hazards identification

IMMUNOSUPPRESSANT, CARCINOGEN EYE May cause irritation or permanent tissue damage. SKIN May cause irritation and contact dermatitis. INGESTION Ingestion may cause irritation. INHALATION Material may be irritating to mucous membranes and upper respiratory tract. ADVERSE SYSTEMIC Serious: Allergic reaction; blood in urine; chest pain; loss of appetite, EFFECTS nausea; fever, chills, new or worsening numbness; seizures, confusion, changes in mood or behavior; yellowing of skin or eyes. Less Serious: Acne, excess hair growth, headache, joint pain, muscle ache, runny or stufrfy nose; stomach upset, diarrhea, constipation; swelling or bleeding gums; tremors. CHRONIC (CANCER) NTP – Yes INFORMATION IARC – YES OSHA – NO An increased incidence of malignancy is shown with patients receiving cyclosporine therapy. (Non Hodgkin’s Lymphoma and skin cancers are the most common types). REPRODUCTION INFO FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women have been conducted. MEDICAL Hypersensitivity to material, current malignancy or premalignant skin CONDITIONS/MEDS lesions, chickenpox (including recent exposure), herpes zoster, impaired AGGRAVATED BY liver or kidney function, and infection. EXPOSURE TARGET ORGANS Immune System, blood. APPEARANCE Capsules. ODOR No information found.